Valeant Faces Wall Street in New Incarnation as Bausch
This article is for subscribers only.
The pharma company formerly known as Valeant still has a lot to prove, beyond a name change.
The innocuously-named Bausch Health Companies Inc. will report second-quarter results Aug. 7, with eyes aptly enough on sales if its biggest business, Bausch + Lomb. The pace of growth for its potential blockbuster gastrointestinal drug Xifaxan will also be under the microscope. Increased transparency into its dermatology business that many have pegged as the driver for its road to recovery will be in focus. Sales in the segment have yet to post a major rebound.